



IDS/ #12  
J 3/26/02  
Patent  
252/029US

TECH CENTER 1600/2900

MAR 20 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: )  
Anna P. Catania, et al. ) Group Art Unit: 1642  
Serial No.: 09/533,341 ) Examiner: Parkin, J.  
Filed: March 23, 2000 )  
For: ANTIMICROBIAL AND ANTI- )  
INFLAMMATORY PEPTIDES FOR USE IN )  
HUMAN IMMUNODEFICIENCY VIRUS )

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Supplemental Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

03/18/2002 CNGUYEN 00000104 09533341

01 FC:126

180.00 OP

LA-229371.1

- This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.
- The fee due under 37 CFR § 1.17(p) is submitted herewith.
- A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- A check in the amount of \$180.00 is enclosed for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Dated: 3/7/02

Respectfully submitted,  
LYON & LYON LLP  
By: Sandra Fujiyama  
Sandra Fujiyama  
Reg. No. 46,713



**22249**

LYON & LYON LLP  
633 W. Fifth Street,  
Suite 4700  
Los Angeles, CA  
90071